tbuckley/cabot-search huggingface dataset:
Near‐Infrared‐I to III Absorption and Emission via Core Engineering of Open‐Shelled Organic Mixed‐Valence Systems
Authors: Qiuyan Song, Manman Xu, Baoli Zhang, Mingxu He, Xindong Guo, Jun Nie, Yue Xing, Xiubing Liang, Yincheng Chang
Journal: Advanced Healthcare Materials (2023)

A novel class of agents is developed based on the core engineering of open-shelled organic mixed-valence (MV) systems, which enable tunable absorption and emission across the near infrared (NIR)-I to III biowindow (700-1850 nm) by adjusting the number of central nitrogen oxidation sites and the length of the conjugated bridge. Organic mixed-valence (MV) systems are synthesized through a one-step partial chemical oxidation of starburst oligoarylamines, with varying nitrogen oxidation sites and conjugated bridge lengths, including tris(4-[diethylamino]phenyl)aminen+ (T4EPAn+ ), N,N,N',N'-tetrakis(4-[diisobutylamino]phenyl)-1,4-phenylenediaminen+ (TPDAn+ ), and N,N,N',N'-tetrakis(4-methoxyphenyl)benzidinen+ (TMPBn+ ). The absorption wavelength of the MV systems redshifted clearly as the number of central nitrogen oxidation sites increased or the conjugated bridge length is prolonged. T4EPAn+ with one central nitrogen oxidation site exhibits fluorescence emission in the range of 900-1400 nm, while TPDAn+ with two central nitrogen oxidation sites demonstrate strong heat generation capabilities. Additionally, the absorption peak of TMPBn+ with a biphenyl conjugated bridge reaches up to 1610 nm. Especially, these MV systems are highly stable for biological applications due to their high steric hindrance and hyperconjugation effect. These characteristics make MV systems promising candidates for constructing NIR-I/II/III emitters and photothermal agents, representing a significant advance toward developing the next generation of NIR-I to III agents.
Recommending Higher Valent Pneumococcal Conjugate Vaccine for Older Adults
Authors: David S. Fedson
Journal: JAMA Internal Medicine (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Fungi as a source of bioactive molecules for the development of longevity medicines
Authors: Yuliia Shevchuk, Kim Kuypers, Georges E Janssens
Journal: Ageing Research Reviews (2023)

Age-related loss of function brings age-related disease, and therefore it is of primary importance to search for interventions that can help minimize detrimental symptoms people deal with in old age. Fungi have always been given a great deal of attention and reverence in traditional medical practices for their ability to minimize harmful symptoms of diseases. More recently, the role of fungi in influencing healthspan and lifespan is being directly studied in the lab. To treat animal model organisms with fungi-derived molecules, extractions from different life cycle stages of fungi are performed. This includes mycelium (the vegetative stage), sporocarps (the reproductive stage), or spores (the end product of the reproductive stage), and each stage provides a variety of bioactive compounds. These bioactive compounds include glycoproteins, polysaccharides, triterpenoids, meroterpenoids, sesquiterpenoids, steroids, alkaloids, benzopyran derivatives, and benzoic acid derivatives, amongst others. In this work, we review evidence that fungal extracts from multiple species can have beneficial effects on the lifespan and healthspan of model organisms, such as C. elegans worms, D. melanogaster flies, and M. musculus mice. We cover extraction methods and lifespan effects of Ganoderma lucidum (i.e. Reishi), Lentinula edodes (i.e. Shiitake), the genus Auricularia (i.e. jelly ear mushrooms), the genera Cordyceps and Ophiocordyceps (e.g. the caterpillar fungi), Hericium erinaceus (i.e. Lion's mane), the mold genus Monascus, and also Inonotus obliquus (i.e. Chaga), Grifola frondosa (i.e. Maitake or hen-of-the-woods), the genus Pleurotus (e.g. oyster mushrooms), and Agaricus subrufescens (i.e. the almond mushroom). We propose that further research on fungal extracts will provide a greater picture of the role fungi-derived bioactive molecules can have in developing longevity and neuroprotective medicines for humans.
Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?
Authors: Jan Philipp Bewersdorf, Scott F. Huntington, Amer M. Zeidan
Journal: Journal of the National Comprehensive Cancer Network (2023)

Acute myeloid leukemia (AML) is the most common acute leukemia in adults in the United States and has seen the approval of several novel agents over the past decade. Similar to treatments for other hematologic and solid malignancies, these novel agents are costly. In the setting of finite financial resources in the healthcare system, the concept of cost-effectiveness analyses has been developed to compare the estimated costs and associated benefits expected with different interventions (eg, drugs, diagnostic tests, procedures). Although drug approvals in the United States are not based on budgetary considerations, cost-effectiveness analyses can inform health policy decisions, resource allocation, and societal debates. However, such analyses are only capturing parts of the costs and benefits to the healthcare system, payers, and consumers, and are based on modeling assumptions with inherent limitations. In addition, cost-effectiveness analyses for several of the novel agents approved for treatment of AML are limited and have reported conflicting results. This review uses cost-effectiveness analyses of azacitidine/venetoclax and liposomal cytarabine/daunorubicin as examples to review considerations and best practices when conducting and interpreting such studies. To ensure adequate interpretability of cost-effectiveness studies, transparency in the model inputs/assumptions, data sources, and funding is of great importance, as evidenced by the discrepant conclusions across studies. Furthermore, the perspective and the healthcare system from which a cost-effectiveness analysis is conducted are important to consider because practice patterns and drug prices between countries can be variable. However, with advances in health economic modeling techniques, adherence to best practices, and increasing public interest in these types of studies, cost-effectiveness analyses can become an important tool to inform various stakeholders in the healthcare system to allocate limited resources most efficiently.
Reply to: “The effects of CFTR modulator therapies on liver stiffness and bile flow: A single-centre experience”
Authors: Jérémy Dana, Dominique Debray, Valérie Vilgrain
Journal: Journal of Hepatology (2023)

We would like to thank Calvo et al.1 for their interest in our recently published review on cystic fibrosis-related liver disease (CFLD).2 CFLD includes two main, sometimes co-existing, manifestations: focal biliary fibrosis and portosinusoidal vascular disease. Furthermore, hepatic steatosis, hypothesised to represent liver involvement and not to be part of CFLD, most often co-exists with CFLD. This overlap in liver manifestations may be confusing when monitoring patients under CFTR modulator therapy.
The Win Ratio Method in Heart Failure Trials: Lessons Learnt From Empulse
Authors: Stuart J. Pocock, João Pedro Ferreira, Timothy J. Collier, Christiane E. Angermann, Jan Biegus, Sean P. Collins, Mikhail Kosiborod, Michael E. Nassif, Piotr Ponikowski, Mitchell A. Psotka, John R. Teerlink, Jasper Tromp, John Gregson, Jonathan P. Blatchford, Cordula Zeller, Adriaan A. Voors
Journal: European Journal of Heart Failure (2023)

The EMPULSE trial evaluated the clinical benefit of empagliflozin versus placebo using the stratified win ratio approach in 530 patients with acute heart failure (HF) after initial stabilization. We aim to elucidate how this method works and what it means, thereby giving guidance for use of the win ratio in future trials.
Annals Graphic Medicine - Break the Chain, Stop the Cycle
Authors: Zainab Haji, Hina Inam
Journal: Annals of Internal Medicine (2023)

Web ExclusivesApril 2023Annals Graphic Medicine - Break the Chain, Stop the CycleFREEZainab Haji, BDS and Hina Inam, FCPSZainab Haji, BDSAga Khan University Hospital, Karachi, Pakistan (Z.H., H.I.)Search for more papers by this author and Hina Inam, FCPSAga Khan University Hospital, Karachi, Pakistan (Z.H., H.I.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G22-0041 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Zainab Haji, BDS; Hina Inam, FCPSAffiliations: Aga Khan University Hospital, Karachi, Pakistan (Z.H., H.I.)Disclosures: Authors have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G22-0041.Author/Illustrator Information: Zainab Haji, BDS, is a dentist, trained for FCPS at The Aga Khan University Hospital, Karachi, Pakistan (e-mail, [email protected]com). Hina Inam, FCPS Cardiothoracic Surgery, is currently a Fellow at Saint Boniface Hospital, Winnipeg, Manitoba (e-mail, [email protected]com).This article was published at Annals.org on 11 April 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics April 2023Volume 176, Issue 4 ePublished: 11 April 2023 Issue Published: April 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Estimated Effect of Parathyroidectomy on Long-Term Kidney Function in Adults With Primary Hyperparathyroidism
Authors: Carolyn D. Seib, Calyani Ganesan, Adam Furst, Alan C. Pao, Glenn M. Chertow, John T. Leppert, Insoo Suh, Maria E. Montez-Rath, Alex H.S. Harris, Amber W. Trickey, Electron Kebebew, Manjula Kurella Tamura
Journal: Annals of Internal Medicine (2023)

Background: Multidisciplinary guidelines recommend parathyroidectomy to slow the progression of chronic kidney disease in patients with primary hyperparathyroidism (PHPT) and an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2. Limited data address the effect of parathyroidectomy on long-term kidney function. Objective: To compare the incidence of a sustained decline in eGFR of at least 50% among patients with PHPT treated with parathyroidectomy versus nonoperative management. Design: Target trial emulation was done using observational data from adults with PHPT, using an extended Cox model with time-varying inverse probability weighting. Setting: Veterans Health Administration. Patients: Patients with a new biochemical diagnosis of PHPT in 2000 to 2019. Measurements: Sustained decline of at least 50% from pretreatment eGFR. Results: Among 43 697 patients with PHPT (mean age, 66.8 years), 2928 (6.7%) had a decline of at least 50% in eGFR over a median follow-up of 4.9 years. The weighted cumulative incidence of eGFR decline was 5.1% at 5 years and 10.8% at 10 years in patients managed with parathyroidectomy, compared with 5.1% and 12.0%, respectively, in those managed nonoperatively. The adjusted hazard of eGFR decline did not differ between parathyroidectomy and nonoperative management (hazard ratio [HR], 0.98 [95% CI, 0.82 to 1.16]). Subgroup analyses found no heterogeneity of treatment effect based on pretreatment kidney function. Parathyroidectomy was associated with a reduced hazard of the primary outcome among patients younger than 60 years (HR, 0.75 [CI, 0.59 to 0.93]) that was not evident among those aged 60 years or older (HR, 1.08 [CI, 0.87 to 1.34]). Limitation: Analyses were done in a predominantly male cohort using observational data. Conclusion: Parathyroidectomy had no effect on long-term kidney function in older adults with PHPT. Potential benefits related to kidney function should not be the primary consideration for PHPT treatment decisions. Primary Funding Source: National Institute on Aging.
Periprocedural Anticoagulation
Authors: Anna L. Parks, Margaret C. Fang
Journal: Annals of Internal Medicine (2023)

Management of patients taking anticoagulants around the time of a procedure is a common and complex clinical scenario. Providing evidence-based care requires estimation of risk for thrombosis and bleeding, knowledge of commonly used medications, multidisciplinary communication and collaboration, and patient engagement and education. This review provides a standardized, evidence-based approach to periprocedural management of anticoagulation, based on current evidence and expert clinical guidelines.
In situ self-assembled organoid for osteochondral tissue regeneration with dual functional units
Authors: Zhen Yang, Bin Wang, Wei Liu, Xiaoke Li, Kaini Liang, Zejun Fan, Jiao Jiao Li, Yudi Niu, Zihao He, Hui Li, Du Wang, Jianjing Lin, Yanan Du, Jianhao Lin, Dan Xing
Journal: Bioactive Materials (2023)

The regeneration of hierarchical osteochondral units is challenging due to difficulties in inducing spatial, directional and controllable differentiation of mesenchymal stem cells (MSCs) into cartilage and bone compartments. Emerging organoid technology offers new opportunities for osteochondral regeneration. In this study, we developed gelatin-based microcryogels customized using hyaluronic acid (HA) and hydroxyapatite (HYP), respectively for inducing cartilage and bone regeneration (denoted as CH-Microcryogels and OS-Microcryogels) through in vivo self-assembly into osteochondral organoids. The customized microcryogels showed good cytocompatibility and induced chondrogenic and osteogenic differentiation of MSCs, while also demonstrating the ability to self-assemble into osteochondral organoids with no delamination in the biphasic cartilage-bone structure. Analysis by mRNA-seq showed that CH-Microcryogels promoted chondrogenic differentiation and inhibited inflammation, while OS-Microcryogels facilitated osteogenic differentiation and suppressed the immune response, by regulating specific signaling pathways. Finally, the in vivo engraftment of pre-differentiated customized microcryogels into canine osteochondral defects resulted in the spontaneous assembly of an osteochondral unit, inducing simultaneous regeneration of both articular cartilage and subchondral bone. In conclusion, this novel approach for generating self-assembling osteochondral organoids utilizing tailor-made microcryogels presents a highly promising avenue for advancing the field of tissue engineering.
How Would You Manage This Patient With Benign Prostatic Hyperplasia?
Authors: Gerald W. Smetana, C. Christopher Smith, Ajay Singla, Howard Libman
Journal: Annals of Internal Medicine (2023)

Lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) are common in older patients assigned male sex at birth, regardless of gender identity, and treatment of these symptoms is therefore common in primary care practice. In 2021, the American Urological Association published guidelines for management of BPH. They recommend using a standardized scoring system such as the International Prostate Symptom Score to help establish a diagnosis and to monitor the efficacy of interventions, α-blockers as the first-choice pharmacotherapy option, and 5α-reductase inhibitors for patients with prostate size estimated to be at least 30 cc. Tadalafil is another option regardless of erectile dysfunction. Combination therapies with α-blockers and 5α-reductase inhibitors, anticholinergic agents, or β3-agonists are effective options. A surgical referral is warranted if the BPH results in chronic kidney disease, refractory urinary retention, or recurrent urinary tract infections; if there is concern for bladder or prostate cancer; or if symptoms do not respond to medical therapy. In this article, a general internal medicine physician and a urologist discuss the treatment options and how they would apply their recommendations to a patient who wishes to learn more about his options.
Interaction of natriuretic peptide levels and ejection fraction on outcomes with dapagliflozin and empagliflozin in heart failure
Authors: Javed Butler, Tariq Jamal Siddiqi, Faiez Zannad, João Pedro Ferreira, Gerasimos Fillipatos, Stefan D. Anker, Milton Packer
Journal: European Journal of Heart Failure (2023)

Table S1: The effect of SGLT-2 inhibition across the range of ejection fraction in heart failure patients. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Issue Information
Authors: Carlo Brugnara, Stephen Ansell, Barbara Bain, Olivier Bernard, Elizabeth Nemeth, David Porter, Rachel Rosovsky, Ayalew Tefferi, Angela Weyand, Joe Tomaszewski, Natasha Archer, Michael Boston, Andrea Auerbach, Kebede Begna, Nora Bennani, Giada Bianchi, Eugene Bingwen, Singapore Leonard, R Brandão, Canada Toronto, Corey Boston, Julio Delgado, Courtney Dinardo, Naseema Houston, Yelena Ginzburg, New York, Elias Jabbour, Nitin Houston, Eirini Jain, Abhishek Mangaonkar, Hira Mian, Canada Hamilton, New Minniti, Donna York, Attilio Neuberg, El Orazi, Eric Paso, Sameer Padron, Mrinal Parikh, Rochester Patnaik, Jun Peng, Jean-Antoine Ribeil, Valeria Santini, Paul Schmidt, Nicholas Short, Richard Stone, Curtis Marcoux, David Marin, Jeremy Ramdial, Gheath Alatrash, Amin Alousi, Betul Oran, Partow Kebriaei, Uday Popat, Katayoun Rezvani, Vaishali Sanchorawala, Ashutosh Wechalekar, Kihyun Kim, Stefan Schönland, Heather Landau, Fiona Kwok, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond Comenzo, Eirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, Sosana Delimpasi, Emmanouil Spanoudakis, Vasiliki Labropoulou, Ioannis Ntanasis-Stathopoulos, Annita-Ioanna Gkioka, Nikos Giannakoulas, Nikolaos Kanellias, Theodosia Papadopoulou, Aggeliki Sevastoudi, Eyrydiki Michalis, Maria Papathanasiou, Maria Kotsopoulou, Anastasia Sioni, Theodora Triantafyllou, Aikaterini Daiou, Mavra Papadatou, Marie-Christine Kyrtsonis, Anastasia Pouli, Ioannis Kostopoulos, Evgenia Verrou
Journal: American Journal of Hematology (2023)

VINITI (All-Russian Institute of Science & Technological Information) • Web of Science ® (Thomson ISI).For submission instructions, subscription and all other information visit: www.wileyonlinelibrary.com/ajh.Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups.Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts.Follow our progress at www.
Heart Failure Following Anti-Inflammatory Medications in Patients With Type 2 Diabetes Mellitus
Authors: Anders Holt, Jarl E. Strange, Nina Nouhravesh, Sebastian Kinnberg Nielsen, Mariam Elmegaard Malik, Anne-Marie Schjerning, Lars Køber, Christian Torp-Pedersen, Gunnar H. Gislason, Patricia McGettigan, Morten Schou, Morten Lamberts
Journal: Journal of the American College of Cardiology (2023)
Utility of a Smartphone Application in Assessing Palmar Circulation Before Radial Artery Harvesting for Coronary Artery Bypass Grafting
Authors: Simon Parlow, Pietro Di Santo, Omar Abdel-Razek, Richard G. Jung, Pouya Motazedian, Lisa Robinson, Hannah Feagan, Baylie Morgan, Jilliane Wade, Hadi Toeg, Talal Al-Atassi, Marc Ruel, Peter Kuhar, Jordan Bernick, George A. Wells, Trevor Simard, Jeffrey A. Marbach, Michael Froeschl, Rebecca Mathew, Marino Labinaz, Vincent Chan, Benjamin Hibbert
Journal: Circulation (2023)
Caveolin-3 Nitration Drives Insulin Resistance in Prediabetic Hearts
Authors: Junichi Sadoshima
Journal: Circulation (2023)

oderate elevation of blood sugar levels, dyslipidemia, obesity, and hypertension are commonly observed in patients with prediabetes.These patients with dysglycemia have an elevated 5-year risk of heart failure when they manifest a higher biomarkerbased risk score reflecting myocardial alteration. 1 Thus, prediabetic conditions likely initiate significant early biochemical changes in the heart even before the heart manifests functional deterioration.This suggests that, in addition to interventions focusing on glycemic control, those directly targeting specific biochemical alterations in the heart may help prevent the development of heart failure in prediabetic patients.